Skip to content

Saxenda side effects: what the label reports

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

The most common Saxenda side effects in adults were nausea (39.3%, against 13.8% on placebo), diarrhea (20.9%), constipation (19.4%), vomiting (15.7%), injection site reactions (13.9%) and headache (13.6%). Those figures come from five placebo-controlled trials in adults with overweight or obesity. The label says the share of patients reporting nausea declined as treatment continued. Tell your prescriber about persistent or severe abdominal pain.

Source: Saxenda FDA label

Key takeaways

  • Nausea, diarrhea, constipation and vomiting lead the adult Saxenda table, and the share reporting nausea declined as treatment continued.
  • Saxenda carries a boxed warning, the strongest kind the FDA requires, about thyroid C-cell tumors.
  • It must not be used with a personal or family history of medullary thyroid carcinoma or with MEN 2.
  • For an allergic reaction, the label says to stop Saxenda and promptly seek medical advice.
  • Report persistent or severe abdominal pain, a racing heartbeat that doesn't settle, dehydration and any planned surgery.

How often it was reported in the label's trials

Saxenda: Table 2. Adverse Reactions Occurring in ≥2% of SAXENDA-treated Adult Patients and More Frequently than Placebo · Adults with overweight or obesity in 5 double-blind, placebo-controlled trials, treated for up to 56 weeks (3 trials), 52 weeks (1 trial) and 32 weeks (1 trial). The hypoglycemia row is for patients with type 2 diabetes not on insulin (Study 2: Saxenda N=423, placebo N=212), defined as blood glucose below 54 mg/dL with or without symptoms.
ReactionPlacebon=1941Saxendan=3384
Nausea13.8%39.3%
Diarrhea9.9%20.9%
Constipation8.5%19.4%
Vomiting3.9%15.7%
Injection Site Reaction10.5%13.9%
Headache12.6%13.6%
Hypoglycemia in T2DM6.6%12.6%
Dyspepsia2.7%9.6%
Fatigue4.6%7.5%
Dizziness5%6.9%
Abdominal Pain3.1%5.4%
Increased Lipase2.2%5.3%
Upper Abdominal Pain2.7%5.1%
Gastroenteritis3.2%4.7%
Gastroesophageal Reflux Disease1.7%4.7%
Abdominal Distension3%4.5%
Eructation0.2%4.5%
Urinary Tract Infection3.1%4.3%
Flatulence2.5%4%
Viral Gastroenteritis1.6%2.8%
Insomnia1.7%2.4%
Dry Mouth1%2.3%
Asthenia0.8%2.1%
Anxiety1.6%2%
Saxenda: Table 3. Adverse Reactions Occurring in ≥3% of SAXENDA-treated Pediatric Patients and More Frequently than Placebo in a 56 Week Clinical Trial · Pediatric patients aged 12 years and older with obesity, without type 2 diabetes, in a 56-week placebo-controlled trial. The hypoglycemia row is defined as blood glucose below 70 mg/dL with symptoms.
ReactionPlacebon=126Saxendan=125
Nausea14.3%42.4%
Vomiting4%34.4%
Diarrhea14.3%22.4%
Hypoglycemia4%15.2%
Gastroenteritis4.8%12.8%
Dizziness3.2%10.4%
Pyrexia7.1%8%
Abdominal discomfort0.8%4.8%
Constipation2.4%4.8%
Dyslipidemia3.2%4.8%
Fatigue3.2%4.8%
Cough3.2%4%
Depression2.4%4%
Dyspepsia2.4%4%
Pain in extremity2.4%4%
Injection site pain3.2%3.2%
Flatulence0%3.2%
Increased Blood Creatine Kinase2.4%3.2%
Increased Lipase0.8%3.2%
Rash0%3.2%

Saxenda: Gastrointestinal reactions overall

In the adult clinical trials, approximately 68% of SAXENDA-treated patients and 39% of placebo-treated patients reported gastrointestinal disorders; the most frequently reported was nausea (39% and 14% of patients treated with SAXENDA and placebo, respectively).

Saxenda: Discontinuation due to gastrointestinal reactions

Most episodes of gastrointestinal events were mild or moderate and did not lead to discontinuation of therapy (6.2% with SAXENDA versus 0.8% with placebo discontinued treatment as a result of gastrointestinal adverse reactions). The percentage of patients reporting nausea declined as treatment continued.

Saxenda: Injection site reactions

The most common reactions, each reported by 1% to 2.5% of SAXENDA-treated patients and more commonly than by placebo-treated patients, included erythema, pruritus, and rash at the injection site.

Saxenda: Gallbladder disease

The majority of SAXENDA-treated patients with adverse events of cholelithiasis and cholecystitis required cholecystectomy.

Saxenda: Hypoglycemia with a sulfonylurea

In this trial, among patients taking a sulfonylurea, hypoglycemia defined as a plasma glucose less than 54 mg/dL with or without symptoms occurred in 31 (28.2%) of 110 SAXENDA-treated patients and 7 (12.7%) of 55 placebo-treated patients.

Saxenda: Hypoglycemia in adults without type 2 diabetes

Spontaneously reported symptomatic episodes of unconfirmed hypoglycemia were reported by 46 (1.6%) of 2,962 SAXENDA-treated patients and 19 (1.1%) of 1,729 placebo-treated patients.

Saxenda: Heart rate increase

At least one resting heart rate exceeding 100 bpm was recorded for 6% of SAXENDA-treated patients compared with 4% of placebo-treated patients, with this occurring at two consecutive study visits for 0.9% and 0.3%, respectively. Tachycardia was reported as an adverse reaction in 0.6% of SAXENDA-treated patients and in 0.1% of placebo-treated patients.

Saxenda: Acute pancreatitis

In SAXENDA clinical trials in adults, acute pancreatitis was confirmed by adjudication in 9 (0.3%) of 3,291 SAXENDA-treated patients and 2 (0.1%) of 1843 placebo-treated patients.

Saxenda: Low blood pressure

Adverse reactions related to hypotension (hypotension, orthostatic hypotension, circulatory collapse, and decreased blood pressure) were reported more frequently with SAXENDA (1.1%) compared with placebo (0.5%) in SAXENDA clinical trials in adults.

Saxenda: Tiredness, taste changes and dizziness

Events of asthenia, fatigue, malaise, dysgeusia and dizziness were mainly reported within the first 12 weeks of treatment with SAXENDA and were often co-reported with gastrointestinal events such as nausea, vomiting, and diarrhea.

Saxenda: Allergic reactions

Urticaria was reported in 0.7% of SAXENDA-treated patients and 0.5% of placebo-treated patients.

Saxenda: Breast cancer

In SAXENDA clinical trials in adults, breast cancer confirmed by adjudication was reported in 17 (0.7%) of 2379 SAXENDA-treated women compared with 3 (0.2%) of 1300 placebo-treated women, including invasive cancer (13 SAXENDA- and 2 placebo-treated women) and ductal carcinoma in situ (4 SAXENDA- and 1 placebo-treated woman).

Saxenda: Lipase and amylase increases

Among SAXENDA-treated patients, 2.1% had a lipase value at anytime during treatment of greater than or equal to 3 times the upper limit of normal compared with 1.0% of placebo-treated patients.

Saxenda: Pediatric discontinuation due to gastrointestinal reactions

In a pediatric clinical trial, 8% of patients treated with SAXENDA versus no patients who received placebo discontinued treatment as a result of gastrointestinal adverse reactions.

Saxenda: Hair loss (alopecia), cutaneous amyloidosis and dysesthesia, postmarketing reports without a rate

The following adverse reactions have been reported during post-approval use of liraglutide, the active ingredient of SAXENDA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

FDA label: Saxenda, Revised: 6/2026 (DailyMed version 22)

Warnings on the Saxenda label

  • Risk of Thyroid C-cell Tumors

    Liraglutide caused thyroid C-cell tumors in rats and mice; whether it does in humans is unknown, and Saxenda is contraindicated with a personal or family history of MTC or with MEN 2.

    It is unknown whether SAXENDA will cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined.
  • Acute Pancreatitis

    Acute pancreatitis, including fatal cases, has been seen with GLP-1 receptor agonists including liraglutide; stop Saxenda if pancreatitis is suspected.

    After initiation of SAXENDA, observe patients carefully for signs and symptoms of acute pancreatitis which may include persistent or severe abdominal pain (sometimes radiating to the back) and which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, discontinue SAXENDA and initiate appropriate management.
  • Acute Gallbladder Disease

    Gallstones were reported in 2.2% of adult Saxenda patients versus 0.8% on placebo, and most affected Saxenda patients needed gallbladder removal.

    In SAXENDA clinical trials in adults, 2.2% of SAXENDA-treated patients reported adverse events of cholelithiasis versus 0.8% of placebo-treated patients. The incidence of cholecystitis was 0.8% in SAXENDA-treated patients versus 0.4% in placebo-treated patients.
  • Hypoglycemia

    Adults with type 2 diabetes on a sulfonylurea or insulin may have a higher risk of low blood sugar with Saxenda, and low blood sugar also occurred in pediatric patients without diabetes.

    Adult patients with type 2 diabetes mellitus on an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia with use of SAXENDA, including severe hypoglycemia.
  • Heart Rate Increase

    Saxenda raised resting heart rate by a mean of 2 to 3 beats per minute versus placebo in adult trials; it should be stopped if a sustained increase occurs.

    Mean increases in resting heart rate of 2 to 3 beats per minute (bpm) were observed with routine clinical monitoring in SAXENDA-treated adult patients compared to placebo in clinical trials. More patients treated with SAXENDA, compared with placebo, had changes from baseline at two consecutive visits of more than 10 bpm (34% versus 19%, respectively) and 20 bpm (5% versus 2%, respectively).
  • Acute Kidney Injury Due to Volume Depletion

    Acute kidney injury, sometimes needing dialysis, has been reported, mostly in people dehydrated by nausea, vomiting or diarrhea.

    There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with liraglutide
  • Severe Gastrointestinal Adverse Reactions

    Severe gastrointestinal reactions were reported in 4.8% of Saxenda patients versus 1.4% on placebo, and Saxenda is not recommended in severe gastroparesis.

    In SAXENDA clinical trials, severe gastrointestinal adverse reactions were reported more frequently among patients receiving SAXENDA (4.8%) than placebo (1.4%). Severe gastrointestinal adverse reactions have also been reported postmarketing with GLP-1 receptor agonists. SAXENDA is not recommended in patients with severe gastroparesis.
  • Hypersensitivity Reactions

    Serious allergic reactions such as anaphylaxis and angioedema have been reported; stop Saxenda and seek medical advice if one occurs.

    If a hypersensitivity reaction occurs, the patient should discontinue SAXENDA and other suspect medications and promptly seek medical advice.
  • Pulmonary Aspiration During General Anesthesia or Deep Sedation

    Because Saxenda slows stomach emptying, rare cases of aspiration during anesthesia or deep sedation have been reported with GLP-1 receptor agonists; tell providers before planned procedures.

    Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking SAXENDA.

If a side effect has you worried, tell your prescriber about persistent or severe abdominal pain, about nausea, vomiting or diarrhea that leaves you dehydrated, and about a racing heartbeat that doesn’t settle. For an allergic reaction, the label says to stop Saxenda and promptly seek medical advice. Other dose decisions belong to your prescriber.

Saxenda (liraglutide) has one of the larger safety tables in this class. The adult figures pool five double-blind, placebo-controlled trials in people with overweight or obesity, with 3384 patients on Saxenda and 1941 on placebo. A placebo group gets an inactive treatment instead of the medicine. A separate 56-week trial covers adolescents aged 12 and older. Both tables appear in full on this page.

What are the most common side effects of Saxenda?

In adults, with the Saxenda figure first and placebo second:

At the injection site, the label says the most common reactions were redness, itching and rash, each reported by 1% to 2.5% of Saxenda patients.

How common are stomach side effects on Saxenda, and when do they happen?

In the adult trials, approximately 68% of Saxenda patients and 39% of placebo patients reported a gastrointestinal (stomach or bowel) disorder. The label says most episodes “were mild or moderate and did not lead to discontinuation of therapy,” and that “the percentage of patients reporting nausea declined as treatment continued.”

It gives a time frame for another group of reactions. Weakness, fatigue, malaise (feeling generally unwell), taste changes and dizziness “were mainly reported within the first 12 weeks of treatment” and were often reported together with nausea, vomiting and diarrhea.

Severe gastrointestinal reactions were reported by 4.8% of Saxenda patients and 1.4% on placebo. The label says Saxenda is not recommended in patients with severe gastroparesis (a stomach that empties very slowly).

What side effects did teens report on Saxenda?

In the 56-week trial in adolescents aged 12 and older with obesity, the leading reactions were nausea (42.4% on Saxenda, 14.3% on placebo), vomiting (34.4% and 4%) and diarrhea (22.4% and 14.3%). Vomiting was about twice as frequent as in the adult table.

Low blood sugar with symptoms, defined as glucose below 70 mg/dL, was reported by 15.2% of adolescents on Saxenda and 4% on placebo. None of them had type 2 diabetes. In that trial, 8% of patients on Saxenda and none on placebo stopped treatment because of gastrointestinal reactions.

What is the boxed warning, and what are the serious side effects?

Saxenda carries a boxed warning for thyroid C-cell tumors. A boxed warning is the strongest kind the FDA requires, set apart in a box on the label. Liraglutide causes these tumors in rats and mice, and the label says it’s unknown whether Saxenda causes them, “including medullary thyroid carcinoma (MTC), in humans.” Saxenda is contraindicated, meaning it must not be used, in patients with a personal or family history of MTC or with MEN 2 (Multiple Endocrine Neoplasia syndrome type 2).

The other warnings, with adult trial figures:

  • Gallbladder disease: gallstones in 2.2% on Saxenda and 0.8% on placebo, gallbladder inflammation in 0.8% and 0.4%. The label says the majority of affected Saxenda patients required gallbladder removal.
  • Acute pancreatitis (inflammation of the pancreas): confirmed in 0.3% of Saxenda patients and 0.1% on placebo.
  • Heart rate: a mean rise of 2 to 3 beats per minute against placebo. Increases of more than 10 beats per minute at two consecutive visits were recorded in 34% on Saxenda and 19% on placebo.
  • Low blood sugar: among adults with type 2 diabetes, 12.6% on Saxenda and 6.6% on placebo had glucose below 54 mg/dL.
  • Low blood pressure: related reactions in 1.1% on Saxenda and 0.5% on placebo.
  • Acute kidney injury, serious allergic reactions and pulmonary aspiration (stomach contents entering the lungs) during anesthesia or deep sedation.

The label also reports that breast cancer was confirmed in 0.7% of women on Saxenda and 0.2% of women on placebo in the adult trials. The safety guide explains the warnings in turn, and the label lists alopecia (hair loss) among reactions reported after approval.

How many people stop Saxenda because of side effects?

In the adult trials, 9.8% of Saxenda patients and 4.3% of placebo patients stopped treatment early because of side effects. The most common reasons were nausea (2.9% against 0.2%), vomiting (1.7%) and diarrhea (1.4% against 0%). Gastrointestinal reactions as a group accounted for 6.2% on Saxenda and 0.8% on placebo.

When to call your prescriber

The label names specific things to report:

  • Persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting. The label lists these as signs of acute pancreatitis.
  • A hypersensitivity (allergic) reaction. The label says the patient should discontinue Saxenda “and promptly seek medical advice.”
  • A racing heartbeat that doesn’t settle. The label addresses a sustained increase in resting heart rate.
  • Nausea, vomiting or diarrhea that leaves you dehydrated.
  • Any planned surgery or procedure. The label tells patients to let their healthcare providers know beforehand that they take Saxenda.

Dose decisions belong to your prescriber. The Saxenda guide covers the rest of the label, and the side effects guide compares each reaction across medicines.

Frequently asked questions

What are the most common side effects of Saxenda?

In adults, nausea was reported by 39.3% of Saxenda patients, diarrhea by 20.9%, constipation by 19.4%, vomiting by 15.7%, injection site reactions by 13.9% and headache by 13.6%. On placebo the same reactions were reported by 13.8%, 9.9%, 8.5%, 3.9%, 10.5% and 12.6%. The figures come from five placebo-controlled trials.

How long do Saxenda side effects last?

The label says the percentage of patients reporting nausea declined as treatment continued. It also says tiredness, taste changes and dizziness were mainly reported within the first 12 weeks of treatment and often came together with nausea, vomiting or diarrhea. Those statements describe the trials as a whole, not what you personally should expect.

Does Saxenda cause hair loss?

Hair loss isn't in the Saxenda trial tables. The label lists alopecia (hair loss) among reactions reported after approval of liraglutide and gives no rate. It notes that such reports are voluntary and come from a group of uncertain size, so it's not always possible to estimate how often they happen or to establish that the drug caused them.

Is Saxenda safe?

The label doesn't answer with a yes or a no. It carries a boxed warning, the strongest kind the FDA requires: liraglutide causes thyroid C-cell tumors in rats and mice, and it's unknown whether Saxenda causes them in humans. Saxenda must not be used by people with a personal or family history of medullary thyroid carcinoma or with MEN 2. Whether it suits you is a decision for your prescriber.

What are the serious side effects of Saxenda?

The label's warnings cover acute pancreatitis, acute gallbladder disease, low blood sugar, a rise in heart rate, acute kidney injury after dehydration, severe stomach and bowel reactions, serious allergic reactions and pulmonary aspiration during anesthesia. Severe stomach and bowel reactions were reported by 4.8% of Saxenda patients and 1.4% on placebo. Gallstones were reported by 2.2% and 0.8%.

Sources (2)

  1. 1.
    FDA label (DailyMed): Saxenda prescribing information, section 4
    “Patients with a personal or family history of medullary thyroid carcinoma (MTC) or patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)”
  2. 2.